The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1481
November 9, 2015
View Complete Issue         Table of Contents 2019 
Budesonide Rectal Foam (Uceris) for Ulcerative Colitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Budesonide Rectal Foam (Uceris) for Ulcerative Colitis
November 9, 2015 (Issue: 1481)
The FDA has approved a rectal foam formulation of the corticosteroid budesonide (Uceris - Salix/Valeant) for induction of remission in patients with active mild to moderate distal ulcerative colitis (UC) extending up to 40 cm from the anal verge....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Budesonide Rectal Foam (Uceris) for Ulcerative Colitis
Article code: 1481c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.